Page 71 - Read Online

Lee et al. J Cancer Metastasis Treat 2021;7:27 https://dx.doi.org/10.20517/2394-4722.2021.58 Page 11 of 18

Figure 3. Elevated expression of SRC-3 in human ATC. (A) Immunohistochemistry (IHC) images for SRC-3 (I), their magnified images
(×2) showing nuclear staining of SRC-3 (II), and quantitative analysis for the IHC results (III) in different stages of human thyroid
cancer. (B) IHC images for Ki-67 (I) in normal thyroid, PTC, and ATC, and correlation plot showing strong positive relationship between
SRC-3 and Ki-67 expression in ATC (II). Significant differences were indicated by asterisks (****P < 0.0001). Scale bars represent 50 μ
m. ATC: Anaplastic thyroid cancer; FTC: follicular thyroid cancer; PTC: papillary thyroid cancer [147] . (Permission from the authors).

Figure 4. Therapeutic efficacy of SI-2 in ATC xenograft mice models. (A, B) Growth curves (A) and weight (B) of THJ-11T (I) and -16T
(II) xenograft tumors treated with vehicle or SI-2. Significant differences are indicated by asterisks (**P < 0.01 and ****P < 0.0001).
[147]
Data represent the mean ± SD .

hormone-positive breast cancer [151,152] . Development of small-molecule inhibitors targeting the transcription-
associated CDKs has been slow, and few have entered into clinical use. Still, growing numbers of studies
have shown strong efficacy of these inhibitors, particularly in a subset of cancers that exhibit the
[10]
[8]
transcriptional addiction, including small cell lung cancer , ovarian cancer , and triple-negative breast
cancer , and T-cell acute lymphoblastic leukemia [Figure 1].
[6]
[9]